Annexon falls on bigger-than-expected quarterly loss

Annexon

12/08/2026 12:05

** Shares of drug developer Annexon ANNX.O fall 5.4% to $5.05 premarket
** ANNX reports Q2 loss of 28 cents/shr vs analysts' average loss estimate of 24 cents/shr, according to LSEG data
** Co's R&D expenses were $46.6 million for the quarter ended June 30, compared to $44.2 million a year ago
** Analysts' on average were expecting $40.6 million in R&D expenses
** Co says the change in R&D expenses is primarily associated with the late-stage trial of its experimental eye-disease drug vonaprument and contract manufacturing expenses of its treatment candidates
** Annexon is developing treatments for neuroinflammatory diseases of the body, brain, and eye
** Up to last close, stock up 6.4% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))